Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cocrystal Pharma, Inc. (COCP) announced the appointment of Fred Hassan to its Board of Directors, expanding the board to six members. Hassan brings over 40 years of experience in the pharmaceutical industry, having held senior roles at major companies and investment firms. His recent $2 million investment in Cocrystal via an at-the-market private placement underscores his confidence in the company's prospects.
The Chairman of the Board, Roger Kornberg, expressed optimism that Hassan's expertise will strengthen corporate governance and help advance Cocrystal's antiviral pipeline. Hassan emphasized the company's potential to develop innovative antiviral therapies using a unique structure-based discovery platform. This announcement signals a strategic move for Cocrystal as it aims to enhance its leadership and drive its research efforts towards commercialization.